Slides
Page 1
| 1 Investor Presentation Electromed, Inc. Investor Presentation August 25, 2026 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies
Page 2
| 2 Investor Presentation Forward Looking Statements Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Page 3
| 3 Investor Presentation Electromed – Who We Are Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. *As of and for 12 months ended 9/30/2025 Key Stats: Headquarters: New Prague, MN Ticker: ELMD Manufacturing: Minnesota, USA Established: 1992 Treatment Focus: HFCWO Employees: 197* LTM Net Revenues: $73.8M* Market Cap: $350M* Cash / Debt: $20.5M / $0.0M* *As of and for the 12 months ended 6/30/2026
Page 4
| 4 Investor Presentation Electromed Highlights » Growing and profitable medical technology company » A leader in the large and expanding airway clearance market » The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement. » Attractive direct-to-patient and provider model » Strong financial profile with attractive gross margins and well-capitalized balance sheet $35.8 $41.7 $48.1 $54.7 $64.0 $73.8 $3.1 $3.0 $4.0 $6.5 $9.7 $13.9 F Y'2 1 F Y'2 2 F Y'2 3 F Y'2 4 F Y'2 5 F Y'2 6 Revenue Operating Income 35% Operating Income CAGR* *FY ‘21 through FY’26
Page 5
| 5 Investor Presentation What is Bronchiectasis (BE)? » Irreversible, chronic lung condition where airways become abnormally widened » Caused by impaired ability to clear mucus, which leads to recurrent inflammation and infections » Mean prevalence of Bronchiectasis in patients with COPD is 54%¹ 1.Chalmers J. and Sethi S. Raising awareness of Bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18. Disease Misdiagnosed Disease Underdiagnosed HFCWO Under-prescribed BE is a condition that is prevalent, but underdiagnosed and often misdiagnosed
Page 6
| 6 Investor Presentation U.S. Market: Large, Growing, Underpenetrated Estimated HFCWO Bronchiectasis penetration, treated population1 Bronchiectasis HFCWO penetration ~16%1 ~166K HFCWO Adopted 1. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database, GUIDEHOUSE 2023 literature review and 2024 S2N HFCWO Claims data. 2. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 35% of BE patients managed by pulmonologists and $10.5K represents the assumed HFCWO ASP. 3. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 4. Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data. ~1 million U.S. BE Diagnosed Estimated Net Bronchiectasis Prevalence, Diagnosed3 Diagnosed BE population has grown at ~12% annually3 4.1 Million U.S. Undiagnosed Estimated Bronchiectasis Prevalence, Undiagnosed With COPD / BE Overlap4 35% of BE patients managed by pulmonologists3 ~$3.1B Estimated Revenue Opportunity for HFCWO Within Primary Pulmonology Callpoint2 ((1 million – 166K) x 35% x $10.5K) = $3.1B2 The Company is expanding awareness within the large BE patient population Potential Total Addressable Market - $15.1B (4.1M x $10.5K)
Page 7
| 7 Investor Presentation How is Bronchiectasis Treated? HFCWO therapy mimics manual Chest Percussion Therapy (CPT) 1 Clear Airways First TM With SmartVest 2 Treat The Infection (Antibiotics) 3 Reduce The Inflammation (Anti-Inflammatories) On average, HFCWO therapy is performed as follows: How does SmartVest HFCWO therapy work? 2x 15 7 Per day Minutes per session Days per week
Page 8
| 8 Investor Presentation SmartVest Clearway HFCWO designed with the patient in mind An Enhanced Patient Experience Sleek and lightweight generator More portable and easier for travel Intuitive user interface for better patient adherence SmartVest® has a well-established reimbursement code from CMS – E0483; the Company estimates it has over 275 million contracted lives in the U.S.
Page 9
| 9 Investor Presentation SmartNotes combines patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management » Proactive, ongoing support: Licensed Respiratory Therapists stay connected with patients and support their therapy utilization » Outcomes Management: Easy-to-read report provides physicians with a comprehensive view of therapy impact Tracking patient outcomes and treatment progress to physicians SmartNotes Patient Progress Report
Page 10
| 10 Investor Presentation “Therapy with SmartVest significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function” - Powner “Therapy with HFCWO demonstrated key health outcomes improved in post- compared to pre- index period: cough, all-cause hospitalizations, pneumonia, and pulmonary hospitalizations” - DeKoven 57 % Reduction in antibiotic prescriptions1 59 % Decrease in hospitalizations1 75 % Fewer emergency department visits2 94 % Of patients would recommend the SmartVest to others3 97 % Of patients report feeling better or the same after SmartVest use3 99 % Of patients report an increase in sputum production3 1. Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38. 2. Sievert CE, et al 2018. Incidence of Bronchiectasis-Related Exacerbation Rates After HFCWO Treatment—A Longitudinal Outcome-Based Study, Respiratory Therapy, 13(2), 38-41. 3. Patient data on file. HFCWO therapy is effective in treating BE patients Clinical Evidence & Patient Satisfaction
Page 11
| 11 Investor Presentation Direct-to-Patient Model Drives an attractive margin profile Manufacturer Home Medical Equipment (HME) Distributor Patient Electromed Patient $$ $$ $$ Traditional Medical Equipment Channel Direct-to-Patient Distribution (Electromed) Electromed expects 78% gross margins to continue improving going forward
Page 12
| 12 Investor Presentation Net Revenue Breakdown - $73.8M (FY’26) 1% 5% 94% By Setting Homecare By Payer Homecare Qualified Referral Volume 76% 3% 19% 2% 48% 50% 2% Home Care1 Hospitals Other Medicare Commercial/Other2 Medicaid Bronchiectasis Cystic Fibrosis Neuromuscular Other 1.Includes $3.3 million from home care distributor revenue 2.Includes Managed Medicare and Managed Medicaid
Page 13
| 13 Investor Presentation Electromed Growth Strategy Leveraging commercial team and reimbursement expertise to accelerate growth Protect and Grow Homecare Core Expand into Natural Adjacencies Acquisition Opportunities Protect and grow Homecare core with current strategy (sales force expansion, payor contracting, market development) as well as converting low prescribers to high prescribers and target high BE diagnosing physicians who are not prescribing SmartVest Leverage existing technology platform – Pediatrics and Hospital (leveraging DTC and GPO contracts) Explore potential inorganic acquisition opportunities
Page 14
| 14 Investor Presentation Capital Allocation Strategy Proven execution against the Company’s priorities Organic Business Growth Generate Free Cash Flow Capital Allocation Potential Strategic Investments Return to Shareholders New Technology & CAPEX investments Sales rep expansion Market development Treat SMART from the Start campaign Payor coverage expansion $3.9 million of shares repurchased in FY26 FY2026 Execution
Page 15
| 15 Investor Presentation Why Invest? Large, expanding chronic lung diseases market Clinically proven technology Broad payor coverage Consistent double-digit organic revenue growth High gross margins, robust cash flow and expanding operating leverage
Page 16
| 16 Investor Presentation Performance vs. Russell Medical Equipment Index (TTM and as of 6/30/2026 Results) Metric ELMD RUS ME Sales Growth 15.3% > 9.8% Gross Margin 78.5% > 53.9% Operating Margin 18.8% > (2.4%)
Page 17
| 17 Investor Presentation Mike Cavanaugh (617) 877-8641 mike.cavanaugh@icrhealthcare.com Jim Cunniff, President & CEO (952) 758-9299 jcunniff@Electromed.com Brad Nagel, CFO (952) 758-9299 bnagel@Electromed.com
Page 18
| 18 Investor Presentation APPENDIX
Page 19
| 19 Investor Presentation Financial Highlights Financial Summary Year Ended (in $ millions, except shares amounts) June 30, 2025 June 30, 2026 Revenues $64.0 $73.8 Gross Profit $50.0 $57.9 Gross margin 78.1% 78.5% Operating income $9.7 $13.9 Operating margin 15.1% 18.8% Net income $7.5 $11.3 Diluted EPS $0.85 $1.30 Diluted Shares 8,914,421 8,688,563 Cash provided by operations $11.4 $9.7